research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
=== Arts, sciences, and education === John DeCuir, 1936: art director and production designer Robert Bruce Merrifield, 1939: biochemist who won the Nobel Prize in Chemistry in 1984 for the invention of solid phase Peptide synthesis
=== Controversies === In July 2019, the British company Reckitt Benckiser Group (RB Group) and its current/former affiliated entities (notably Indivior, which split from RB Group in 2014) settled with the US Department of Justice (DOJ) regarding the sale and marketing of brand name Suboxone (buprenorphine/naloxone). The non-prosecution agreement involves RB Group paying up to $1.4 billion, the largest settlement payment in U.S. history involving an opioid-class medication. This record was surpassed in October 2020, when Purdue Pharma reached an $8 billion settlement for claims related to injuries and deaths caused by the opioid epidemic, which includes criminal fines, forfeiture, and civil damages. The 2019 case alleged anti-competitive behavior by RB Group and Indivior surrounding the expiration of their regulatory exclusivity for Suboxone sublingual tablets. The DOJ alleged that RB Group and Indivior employed a product hopping scheme (when a firm ceases production of a product upon expiration of regulatory exclusivity in favor of another product that still has regulatory exclusivity in order to prevent generic manufacturer competition) by misrepresenting that the Suboxone sublingual film formulation was safer than the sublingual tablet formulation because "children are less likely to be accidentally exposed to the film product". There was no scientific evidence for that claim.
=== Legal status === In September 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zynlonta, intended for the treatment of adults with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The applicant for this medicinal product is ADC Therapeutics (NL) B.V. Loncastuximab tesirine was approved for medical use in the European Union in December 2022.
==== Employee opposition to AI militarisation ==== In May 2026, workers at Google DeepMind's London headquarters voted to unionise, requesting joint representation by the Communication Workers Union (CWU) and Unite the Union. The unionisation drive was heavily motivated by ethical concerns regarding Google's military-industrial AI contracts, specifically the provision of AI technology to the US Department of Defense and the Israeli military.
The white shark has a stocky, torpedo-shaped body with a short, cone-shaped snout. Its long gill slits do not reach around the head. It has a large triangular first dorsal fin, which partly lines up with the pectoral fins, and a tiny second dorsal fin. The tail fin has two lobes of similar size and a single ridge or keel, and the anal fin is tiny. The white shark has a countershaded coloration for camouflage; being dark on top, usually blue-gray or gray-brown, with a white underside. It also has black tips on the underside of the pectoral fins. There is evidence that the species can change pigments, adding dark pigment or melanin to blotches of white over the course of months. The skin is covered in dermal denticles (tooth-like scales), which are proportionally smaller than in other sharks and have a three-to-five-ridged surface, with each ridge having tips that point backwards.
Sources: en.wikipedia.org
One of the earliest patents for a "chain sawing machine" comprising a chain of links carrying saw teeth was granted to Frederick L. Magaw of Flatlands, New York, in 1883, apparently for the purpose of producing boards by stretching the chain between grooved drums. A later patent incorporating a guide frame was granted to Samuel J. Bens of San Francisco on January 17, 1905, his intent being to fell giant redwoods. The first portable chainsaw was developed and patented in 1918 by Canadian millwright James Shand. After he allowed his rights to lapse in 1930, his invention was further developed by what became the German company Festo in 1933. The company, now operating as Festool, produces portable power tools. Other important contributors to the modern chainsaw are Joseph Buford Cox and Andreas Stihl; the latter patented and developed an electric chainsaw for use on log bucking sites in 1926 and a gasoline-powered chainsaw in 1929, and founded a company to mass-produce them. In 1927, Emil Lerp, the founder of Dolmar, developed the world's first gasoline-powered chainsaw and mass-produced them. World War II interrupted the supply of German chainsaws to North America, so new manufacturers sprang up, including Industrial Engineering Ltd (IEL) in 1939, the forerunner of Pioneer Saws Ltd and part of Outboard Marine Corporation, the oldest manufacturer of chainsaws in North America. The first one-man chainsaw was introduced in 1950, though it was relatively heavy.
On July 22, 2025, the United States informed of its decision to withdraw from UNESCO, effective December 31, 2026. In a presidential memorandum issued on January 7, 2026, Donald Trump directed to start the process of withdrawal of the US from the 66 organizations, agencies and commissions of the United Nations, including UN Framework Convention on Climate Change (UNFCCC), calling them "contrary to the interests of the United States".
The web was completed the following day. The crew members were prompted to expand the initial protocol. They fed and watered the spiders, giving them a house fly. The first web was removed on August 13 to allow the spider to construct a second web. At first, the spider failed to construct a new web. When given more water, it built a second web. This time, it was more elaborate than the first. Both spiders died during the mission, possibly from dehydration. When scientists were given the opportunity to study the webs, they discovered that the space webs were finer than normal Earth webs, and although the patterns of the web were not totally dissimilar, variations were spotted, and there was a definite difference in the characteristics of the web. Additionally, while the webs were finer overall, the space web had variations in thickness in places: some places were slightly thinner, and others slightly thicker. This was unusual, because Earth webs have been observed to have uniform thickness. Later experiments indicated that having access to a light source could orient the spiders and enable them to build their normal asymmetric webs when gravity was not a factor.
Yo-Chi is an Australian frozen yogurt franchise providing self-serve frozen yogurt. Opening its first store in 2012, following slow growth and two acquisitions, the chain has experienced rapid growth in the 2020's, with the brand being particularly popular amongst Generation Z.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.